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Abstract
The current challenge for healthcare systems is to assess the clinical and economic value of non-drug technologies. Attempts have been made 
to use Health Technology Assessment, a standard method used in many countries to assess and make decisions regarding the reimbursement of 
medicines. The use of health technology assessment for non-drug technology can be a challenge because of the lower availability of high-quality 
scientific evidence in comparison with drugs. In several European countries attempts were made to develop guidelines for the clinical and economic 
evaluation of non-drug technologies; we presented specific guidelines prepared by British and French HTA agencies: NICE and HAS, respectively. 
In the case of Poland, the role of the Agency for Health Technology Assessment and Tariff System (AOTMiT) is to assess and appraise all medical 
technologies and services claiming public money funding; most of these assessments concern drug technologies. Only 103 of 1,550 orders (6.6%) 
issued by the Ministry of Health, from 1st January 2012 to 1st July 2018, were related to non-drug technologies. The health services assessed by the 
AOTMiT include different non-drug medical technologies, both specialized medical devices as well as surgical interventions or diagnostic proce-
dures or screenings. Orders for non-drug technologies issued by the Ministry of Health vary in scope and type of assessment.
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Przygotowanie do wydania elektronicznego finansowane w ramach umowy  
641/P-DUN/2018 ze środków Ministra Nauki i Szkolnictwa Wyższego  
przeznaczonych na działalność upowszechniającą naukę.
In European Union countries, decisions for reimburse-
ment of medicines are commonly based on the Health 
Technology Assessment (HTA); however, changes are 
happening much more slowly in the scope of legal re-
gulations concerning requirements for introducing non-
-drug technologies (including medical devices) into the 
reimbursement list with the use of analogous tools.
Non-drug technologies can be of both therapuetic and 
diagnostic nature, or supportive in the case of disability. 
They include surgery techniques, intervention therapies 
(e.g. angioplasty) and medical devices (e.g. stents, car-
diac pacemakers or orthopedic appliances).
The use of health technology assessment in rela-
tion to non-drug technologies can pose a challenge 
due to the quality of scientific evidence and the fact 
that such technologies may have various purposes and 
applications. Differences between the possibilities of 
assessing drug technologies and non-drug technologies 
result from the way the latter are marketed – namely, 
they do not require a presentation of detailed data 
derived from rigorously conducted clinical trials on 
efficacy and safety, nor undergo the admission proce-
dure in the registration institution, as is the case with 
medicines [1]. 
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The main problem with assessing non-drug tech-
nologies is the lower number of published scientific 
evidence (results of clinical trials). Moreover, there are 
fewer possibilities to compensate for high research costs 
of non-drug technologies with a short life cycle. What 
is more, the manufacturers of non-drug technologies, in 
contrast to pharmaceutical companies producing drugs, 
are mostly small entrepreneurs with small capital and 
limited experience in conducting clinical trials, and the 
problem is not only the small number of tests, but also 
their quality. Unlike in case of drugs, there are rare and 
usually methodologically limited clinical trials for non-
-drug technologies, and existing requirements in authori-
sation procedures are less challenging than those for drug 
testing. Available research for non-drug technologies of-
ten focuses on endpoints, the usefulness of which during 
clinical evaluation is limited; moreover, such studies are 
often planned without a control group [2].
Another problem when assessing non-drug technolo-
gies is the moment of their evaluation. These technolo-
gies are usually assessed in the initial phase of their lives, 
when the number of studies regarding their effectiveness 
is still very small. Therefore, data should be allowed 
from audits, unpublished studies (‘data on file’) or from 
conference abstracts, which may have lower reliability 
compared to randomized clinical trials, but on the other 
hand it will allow assessing the effectiveness of non-drug 
technologies.
Short product lifetime and frequent modifications 
(appearance of various types of these technologies) may 
affect the change in effectiveness and be a further im-
pediment to a reliable clinical assessment for non-drug 
technologies. Similar technologies can also be produced 
by different manufacturers, further hindering their proper 
assessment.
It is not only the evaluation of clinical effectiveness 
(and safety profile) of non-drug technologies that is dif-
ficult to perform, but also the assessment of costs. The 
costs of non-drug technology are usually complex and 
consist of the cost of the technology itself and its imple-
mentation in patients and, importantly, they can change 
over time.
In contrast to drugs, in the case of non-drug techno-
logies there are many additional factors that affect their 
effectiveness, including the conditions in which they are 
used, and the experience and competences of employees 
who operate or use them. This relationship is called ‘le-
arning curve’ and should also be included in economic 
models used for non-drug technology assessments [1–4].
Non-drug technologies are evaluated in Polish condi-
tions by the Agency for Health Technology Assessment 
and Tariff System (pol. Agencja Oceny Technologii 
Medycznych i Taryfikacji, AOTMiT) on the Ministry of 
Health (pol. Ministerstwo Zdrowia, MZ) order. However, 
the scale of such assessment is much lower than in the 
case of medicines. Between the year 2012 and 1st July 
2018, the MZ issued to the AOTMiT a total of 1,550 or-
ders, the vast majority of which (91.2%) concerned drug 
technologies – mainly medicinal products, but also few 
special purpose dietary supplements. The aim of 33.4% 
of MZ orders was to prepare the AOTMiT verification 
analysis for drugs and to determine the official sales pri-
ce. Other orders (8.8% of all orders issued by MZ – 137 
in total) included health services/non-drug technologies 
(6.6%, 103 orders), or concerned the preparation of the 
opinions on programmes, including national health pro-
grammes, issued mainly on the basis of Art. 48(2a) of the 
Act of 27 August 2004 on health care benefits financed 
from public funds (34 orders) (Figure 1) [5–9].
MZ orders regarding non-drug technologies were is-
sued mainly on the basis of Art. 31c or Art. 31n(5) of 
the Act, or – though much less frequently – according to 
Art. 31e of the Act (7 MZ orders during the considered 
period) [5]. Among health care services assessed by the 
AOTMiT or still undergoing assessment, there are very 
diverse non-drug medical technologies, including techni-
cal medical devices, e.g. speech processors for brainstem 
implants or sound processors in auditory implants (MZ 
order no. 98/2018 of 1st June 2018), as well as surgical 
interventions, such as prophylactic mastectomy in wo-
men with high to very high risk of breast cancer deve-
lopment (MZ order no. 39/2018 of 6th February 2018) or 
diagnostic procedures, including the SATRO ECG diag-
nostic method based on ECG analysis and early detection 
of heart diseases (MZ order no. 4/2018 of 11th January 
2018) or screening tests (e.g. MZ order no. 47/2017 of 
29th March 2017), including evaluation of the screening 
system allowing for early diagnosis of cognitive deficien-
cies and dementia [5–9].
MZ orders concerning non-drug technologies 
vary in scope and cover different aspects of the as-
sessment. Among MZ orders there are those covering 
only the preparation of a systematic review, i.e. the as-
sessment of clinical effectiveness (e.g. MZ order no. 
98/2018 indicated above) or orders regarding only the 
economic aspects, inluding budget impact (e.g. MZ 
order no. 132/2017 regarding the determination of the 
threshold price for cytological advice, preparation of sup- 
ply and demand forecasts and the impact on the payer’s 
budget), or covering the preparation of a report on the 
validity of qualifying for a guaranteed benefit package 
(e.g. MZ order no. 48/2017 regarding the evaluation of 
electroconvulsive therapy for patients with mental disor-
ders) [5–9] (Table I).
In EU countries, methods of conducting advanced 
assessments of non-drug technologies are still being de-
veloped, and the agencies assessing medical technologies 
are using different ways to solve the problems that arise 
during the assessment. In 2009, the British National In-
stitute for Health and Care Excellence (NICE), launched 
a Medical Technologies Evaluation Programme (MTEP) 
which aim was to identify new diagnostic technologies 
and procedures, evaluate them using standard NICE 
methods, and then, if necessary, introduce them into ge-
neral use. A great number of subjects participated in the 
creation of the programme, including clinicians, patients’ 
groups, representatives of the medical devices’ manu-
facturers, payers, managers of medical services and the 
government. It was agreed that non-drug technologies 
should be compared with the current way of proceeding, 
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and the evaluation process should include two stages; 
firstly, it should be decided whether a given technology 
is worth further evaluation. Secondly, a detailed analysis 
should be carried out based on the cost-consequence mo-
del, which allows calculating whether a given technology 
generates savings in relation to the current care and how 
big are those savings. The manufacturer of a medical de-
vice should provide evidence not only that their product 
works, but that it is applicable in everyday practice and 
brings benefits for patients. The manufacturer should also 
define the current clinical practice that will be replaced or 
limited by the evaluated product. Different aspects are ta-
ken into account in the technology assessment, including: 
improving the health outcomes of patients, their quality 
of life or survival, decreasing the number of hospitaliza-
tions or shortening the time of hospitalization, the pos- 
sibility of treating patients in an outpatient rather than 
inpatient setting, reducing the number of medical staffs’ 
working hours as a result of the introduction of a given 
technology, and other factors affecting the reduction of 
costs, including costs of complications’ treatment, trans-
port and energy. The decision regarding the recommen-
dation of a given technology largerly depends on the 
experts’ opinion, but also on the opinion of patients and 
specialists in a given field [2, 10]. 
The solution used in Great Britain, concerned the 
non-drug technologies’ assessment, deserves attention 
because it takes into account the most important aspects 
related to its application. Due to the lack of clinical trials 
for non-drug technologies or their low quality, the emp-
hasis is placed on the opinion of clinical experts and other 
interested parties, in particular patients who can benefit 
from the introduction of a given technology. In contrast 
to drug technologies, non-drug technologies allow to per-
form the analysis based on conference-derived informa-
tion, reports, or other publications that have significantly 
lower quality compared to randomized clinical trials con-
ducted for medicines. In addition, as part of the econo-
mic assessment, the recommended analytical technique 
is the cost-consequence analysis, which is sufficient to 
indicate the possible savings generated by replacing the 
current practice with the assessed non-drug technology. 
Due to the fact that in the vast majority of cases a reliable 
comparison of the effectiveness of the assessed non-drug 
technology with current practice is not possible, great im-
portance is attached to the assessment of the benefits that 
a given technology can bring to patients [2, 10].
A publication of the French agency specializing in the 
assessment of medical technologies, Haute Autorité de 
Santé (HAS), is also noteworthy as it presents an opti-
mal methodology of clinical trials providing data on the 
effectiveness and safety of medical devices which are 
necessary to issue reimbursement decisions [11]. The 
requirements outlined are similar to those for medici-
nes; however, it was distinguished into the evaluation of 
medical device with medical procedure which is needed 
for its use or the evaluation of the medical device solely. 
The document was prepared for manufacturers, research 
organizations and project creators. The aim of the stu-
dy was to identify a set of methods and conditions that 
would allow high-quality clinical evaluation, especially 
when conventional randomized clinical trials cannot be 
performed. The review of comparative methods that can 
be used to assess the potential clinical benefits of non-
-drug technology should greatly facilitate the reimburse-
ment process [11].
2012 2013 2014 2015 2016 2017 H1 2018
Total of MZ orders 132 352 292 219 227 207 121
Orders concerning the preparation of 
verification analyses (medicines and special 
purpose dietary supplements)
67 80 102 88 74 78 29
Remaining orders concerning medicines and 
special purpose dietary supplements 49 265 183 102 131 100 65
Orders concerning preparation of the opinions 
on drafts of health programmes 3 1 4 3 6 10 7
Orders concerning preparation of the opi-
nions on non-drug technologies 13 6 3 26 16 19 20
Figure 1. MZ orders issued to AOTMiT in 2012 – H1 2018.
Source: Own calculations based on the data available on the AOTMiT website (http://www.aotm.gov.pl). 
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MZ order 
number in 
a given year
The scope of the MZ order
Legal basis – Act on 
healthcare services 
financed from public 
funds [6]
2018 (first half)
2 Educational benefit in the field of diabetology in patients with diabetes, as a guaranteed benefit within outpatient specialist care Art. 31 c, section 1
4 Diagnostic method of SATRO-ECG based on ECG analysis and early detection of heart disease as a guaranteed benefit within primary health care Art. 31 c, section 1 
5 Corneal cross-linking surgery as a guaranteed benefit Art. 31 n (5)
6
Assessment of the quality and usefulness of scientific evidence in terms of its possible use as a source 
of information for making a clinical decision on whether or not to use the therapy, based on the 
webpage: www.haptens.republika.pl/haptenology pl.html
Art. 31 n (5)
30
Preparation of recommendations of the Agency President regarding the justification of qualifying health 
care benefits as guaranteed benefits, including an opinion on the genetic research financing model and 
a proposal of conditions for the implementation in accordance with the recommended model of organi-
zation and financing of genetic research in outpatient health care: (1) A microarray-based Comparative 
Genomic Hybridazation; (2) Gene expression profiling – various diagnostic sets dedicated to individual 
cancers; (3) C-Ig-FISH (set of probes) (Cytoplasmic Immunoglobulin FISH) genetic test; (4) Analysis of 
the expression of a gene or several genes (including fusion genes) using the real-time polymerase chain 
reaction; (5) Whole-exome sequencing using the next-generation sequencing technology in diagnosing 
genetically conditioned diseases; (6) BACS-on-Beads technology – in diagnosing prenatal abnormali-
ties of fetal development and structural defects; (7) Rapid-FISH (fluorescence in situ hybridization) in 
diagnosing selected aneuploidies; (8) Clinical exom sequencing (panel of > 4,500 genes with well-docu-
mented clinical significance) using the next-generation sequencing technology in diagnosing genetically 
conditioned diseases; (9) Genetic test – (rapid, fluorescence in situ hybridization), prenatal test for aneu-
ploidy, set of probes; (10) MLPA (multiplex ligation-dependent probe amplification) in pre-natal digno-
stics; (11) Analysis of 40 or more amplicons or more than 9 kb of the coding sequence of the tested gene 
or analysis of several genes or the use of microarrays (methylation, expression, chip-on-chip); 
(12) Simple diagnostics not related to a specific disease entity (e.g. twins research, feedback analysis, 
STR analysis – Short Tandem Repeat, VNTR – Variable Number Tandem Repeat)
Art. 31 c, section 1
38 Treatment of diabetic foot syndrome as a guaranteed benefit within outpatient specialist care and hospital treatment Art. 31 c, section 1
39 Prophylactic mastectomy in a group of women with high to very high risk of developing breast cancer as a guaranteed benefit within hospital treatment Art. 31 c, section 1
40 Transurethral resection of a bladder tumour in blue light using a photosensitizer (TURBT-PDD) as a guaranteed benefit within hospital treatment Art. 31 c, section 1
57 Assessment of the justification of changing the medical technology of all guaranteed services in the areas of: basic health care, outpatient specialist care and hospital treatment Art. 31(e)
72
(1) “Invasive pre-operative diagnostics to locate an epileptogenic focus – placement of intracranial 
electrodes for long-term video-EEG monitoring”; (2) ”The surgical procedure to remove an epilepto-
genic focus (one operation) with intraoperative EEG monitoring, electrocorticography with simultane-
ous functional brain monitoring (MEP, SSEP, BAEP), excitatory speech function”, indication: epilepsy 
(ICD-10: G40.0, G40.1, G40.2) as guaranteed benefits within hospital treatment
Art. 31 c, section 1
73 Bronchial thermoplasty, indication: severe asthma as a guaranteed benefit in the field of hospital treatment Art. 31 c, section 1
74 Daily long-term medical care as a guaranteed benefit within care and caring services as part of long-term care Art. 31 c, section 1
82
Preparation of an analytical study on the possibility of using – in the ongoing programme of HBV and 
HCV prophylaxis – fast and cheap anti-HCV tests and tests confirming HBsAg, in which the blood is 
collected for examination from the finger rather than from the vein
Art. 31 n (5)
83
Evaluation of the justification of changing medical technology reagrding the definition of palliative 
and hospice care as well as regarding the indications being the basis for qualifying for palliative and 
hospice care
Art. 31 e
86
Indication of the scope of convergence of recommendations and health care benefits included in the 
”Guidelines for physicians referring patients for imaging”, issued by the National Centre for Radio-
logical Protection in Health Care, with guaranteed benefits specified in the Regulation of the Minister 
of Health of 6 November 2013 on guaranteed benefits within outpatient specialist care (Journal of 
Laws of 2016, item 357, as amended) in Annex 2: list of guaranteed services in the case of diagnostic 
tests and conditions for their implementation: computed tomography (part VI) and magnetic resonance 
(part VIII)
Art. 31 n (5)
89
Elaboration undergoing a consultation process involving a range of interested parties within the health 
care system, appropriate solutions in the provision of comprehensive oncologic care in the field of 
organ cancers, i.e. breast cancer, lung cancer, colon cancer, prostate cancer, gynecological oncology 
(keeping in mind the schedule of works, adopted in the field of neoplastic diseases, taking into account 
the development of recommendations, indicators, the project of the coordinating centre in a given area, 
as well as a comprehensive guaranteed benefit) and preparation of the opinion of the Transparency 
Council and Agency President, project of the coordinating centre in a given area, based on the dead-
lines defined in the attached schedule
Art. 31 n (5)
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MZ order 
number in 
a given year
The scope of the MZ order
Legal basis – Act on 
healthcare services 
financed from public 
funds [6]
92 Evaluation of the justification of changing medical technology within medical rehabilitation Art. 31 e
97
Monitoring of L-asparaginase activity in patients with lymphoproliferative disorders. Indications 
according to ICD-10 codes: C91.0, C83.0, C83.1, C83.2, C83.3, C83.4, C83.5, C83.6, C83.7, C83.8, 
C83.9 , C85, C85.0, C85.1, C85.7, C85.9 implemented as part of hospital treatment and outpatient 
specialist care.
Art. 31 c, section 1
98
Preparation of a systematic review and presentation of opinions on the clinical and practical effective-
ness and safety of speech processors in cochlear implants fixed to the brainstem of patients and sound 
processors in other auditory implants.
Art. 31 n (5)
101 Preparation of the opinion of the AOTMiT President regarding recommendations for the treatment and diagnosis of breast cancer in the version from 8 June, 2018. Art. 31 n (4a)
2017
21 Cardiovascular diseases as a guaranteed benefit within primary health care Art. 31 c
33 Development of solutions in the scope of providing comprehensive oncologic care: “comprehensive care for patients with breast cancer (Breast Cancer Unit)” Art. 31 n (5)
44 Indication of groups of medical devices constituting a significant cost of individual guaranteed benefits, such as hospital treatment Art. 31 n (5)
47 The justification of introducing a screening system allowing for early diagnosis of cognitive disorders and dementia Art. 31 n (5)
48
Preparation of a report on the justification of qualifying as guaranteed benefit in the field of psychi-
atric care and addiction treatment, the guaranteed benefit of electroconvulsive therapy for patients 
with mental disorders [indication: life support] – to guaranteed benefit – electroconvulsive therapy for 
patients with mental disorders 
Art. 31 n (5)
73 The justification of making changes in the description of the benefit “continuous glucose monitoring system (CGM) in people with diabetes” Art. 31 n (5)
94 Recommendations for the diagnosis and treatment in the fields of: oncologic surgery, oncologic gyne-cology, pediatric oncology and hematology, developed by relevant scientific societies Art. 31 n (4a)
100 Evaluation of fluoride prophylaxis Art. 31 n (5)
120
The justification of introducing diagnostic tests ordered by the doctor, anti-HCV examination and 
defining a population in which it would be possible to perform the test according to the criteria 
specified in the order
Art. 31 n (5)
132
Determination of the threshold valuation of cytological counselling carried out according to the sched-
ule of the prevention programme and early detection of cervical cancer; Preparation of the forecast of 
supply and demand and the impact on the payer’s budget, taking into account the assumption concern-
ing the estimated threshold valuation.
Art. 31 n (5)
141
Prophylactic removal of ovaries and fallopian tubes reducing the risk of ovarian and fallopian tube 
cancer in carriers of pathogenic mutations in BRCA 1/2 genes as a guaranteed benefit in the field of 
hospital treatment
Art. 31 c, section 1
142 Care for the infertile couple as a guaranteed benefit within outpatient specialist care and hospital treatment Art. 31 c, section 1
143 Peripheral angioplasty of the lower limbs (femoral and popliteal arteries) using the drug-eluting balloon as a guaranteed benefit within hospital treatment Art. 31 c, section 1
160 Replacement of a subcutaneous implantable cardioverter-defibrillator as a guaranteed benefit within hospital treatment Art. 31 c, section 1
175 Extension of the list of medical devices issued on behalf of a continuous glucose monitoring system requiring the involvement of the patient without help or participation of professionals Art. 31 n (5)
194 Liquid-based cytology as part of a cervical cancer prevention programme as a guaranteed benefit within health programmess Art. 31 c, section 1
199
Qualification of healthcare benefit: “Dietary recommendation for pregnant women and parents, cus-
tomary primary carer or statutory representative of children from 6 months of age up to the age of 5”, 
as guaranteed benefits within health care and outpatient specialist care
Art. 31 c, section 1
200 Evaluation of the justification of the change of medical technology regarding diagnostic tests of the CT and MR within outpatient specialist care Art. 31 c, section 1
201
1. Relaxing bite splint; 2. X-ray diagnostics – pantomographic image with description once every 5 
years; 3. Full upper overdentures based on protected roots; Full lower overdentures based on protected 
roots, as guaranteed services in the field of dental treatment
Art. 31 c, section 1
2016
66
Percutaneous endoscopic gastrostomy – PEG for the purpose of nourishing a patient who cannot take 
oral food, suffering from congenital disease associated with deficiency of clotting factors (haemophilia) 
versus other possible ways of eating (e.g. nasogastric intubation, enteral feeding, parenteral nutrition 
with a possible anticoagulant shield)
Art. 31 n (5)
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healthcare services 
financed from public 
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67
Preparation of an elaboration containing cost data and financial implications for the health care system, 
in the part concerning the planned conditions for the performance of the service: Comprehensive treat-
ment of chronic and complicated wounds, including: wound dressing; relief; local pressure therapy; 
antibiotic intravenous therapy; foot amputations; outpatient skin grafts; compression therapy.
Art. 31 n (5)
150 Treatment of acute or chronic graft-versus-host disease (GvHD) resistant to corticosteroids using extracorporeal photopheresis (ECP) Art. 31 n (5)
151 Efficacy and safety of treatment of atherosclerosis in patients with chelatones (EDTA) Art. 31 n (5)
152 Qualifying as a guaranteed benefit in the field of hospital treatment a comprehensive project for the care of patients following myocardial infarction Art. 31 c
153 Qualifying as a guaranteed benefit in the field of hospital treatment a comprehensive care project for patients undergoing hip arthroplasty Art. 31 c
188 LDL-apheresis, used in homozygous or heterozygous hypercholesterolemia after 3 months of ineffective treatment using diet and cholesterol-lowering drugs Art. 31 n (5)
196 Sleeve gastrectomy: Gastric bypass using the Roux-en-Y method; Gastric bypass using the mini gastric bypass method – Surgical treatment of obesity. Art. 31 c
209
Assessment of the justification of qualifying for guaranteed benefits within palliative and hospice care 
solutions in the scope of benefits for pregnant women with suspected fetal malformations, including 
a presentation on the solutions
Art. 31 n (5)
211
In cooperation with the Centre of Health Care Information Systems, developing an electronic base 
of guaranteed benefits, which will be prepared in accordance with the structure of the description of 
benefits accepted by the Minister of Health
Art. 31 n (5)
212 Comparing the effectiveness of peritoneal dialysis with hemodialysis, and indicating whether there are reasons to create conditions conducive to one of the methods. Art. 31 n (5)
215
In consultation with a group of interested parties within the health care system, proposing solutions 
in the scope of medical rehabilitation benefits aimed at improving the availability of the benefits in 
question
Art. 31 n (5)
217 Treatment of haemochromatosis with phlebotomy Art. 31 n (5)
218 Detailed assessment of clinical, economic and budget impact of therapeutic hypothermia Art. 31 n (5)
219 Application of the da Vinci surgical system in the following indications: colorectal cancer, prostate cancer, endometrial cancer Art. 31 n (5)
220 Perinatal palliative care Art. 31 c
2015
16 Diagnosis and modification of treatment of patients with monogenic diabetes Art. 31 c
17 Continuous glucose monitoring system for people with diabetes (CGM) – as guaranteed benefits within outpatient specialist care Art. 31 c
18 Corneal cross-linking surgery (X-linking) Art. 31 c
19 Percutaneous balloon angioplasty of pulmonary arteries in the treatment of thromboembolic pulmonary hypertension – as guaranteed benefits in hospital treatment Art. 31 c
29
Additional costs of continuous epidural anesthesia during delivery not included in the DRG [diagnosis-
related group; Pol. JGP] value presented by the NZF. This benefit is dedicated to aggregation with 
groups JGP N01, N02, N03, N09, N11, N13 and will concern vaginal deliveries
Art. 31 n (5)
31
Preparation of a short report on the inclusion of the diagnosis of multiple sclerosis (ICD-10: G35) into 
the list of incurable, progressive life-limiting diseases in which guaranteed benefits in palliative and 
hospice care are provided.
Art. 31 c
69
Preparation of a short report regarding the qualification of the ‘implantoprosthetic treatment’ as a 
guaranteed benefit for service recipients following surgical treatment of facial and cranial cancers in 
the field of dental treatment.
Art. 31 c
90
Proton radiotherapy of cancers located outside the eye, as a guaranteed benefit in the field of hospital 
treatment, together with defining the qualification criteria, based on the principles of Evidence-based 
Medicine, and establishing the cost of treatment
Art. 31 c
110 Treatment of adults with coma (underlying disease ICD-10 R40.2) Art. 31 c
111 Determination of the cost rate for guaranteed health services in the field of dental treatment in children Art. 31 n (5)
113 Determining the cost rate of guaranteed health services in the field of imaging diagnostics performed in children, which – for their proper implementation – require the use of anesthesia Art. 31 n (5)
115
Physiotherapy treatment performed at home – extending the period of service from 6 months to 12 
months, in the case of people who underwent fractures, injuries and amputations of the lower limbs, 
referred to in §6, section 2.7 of the MZ Regulation of 6 November, 2013 on guaranteed benefits within 
medical rehabilitation (Journal of Laws, item 1522)
Art. 31 c
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116
Dental treatment under general anesthesia for uncooperative children, as part of the benefits included 
in Annex 3 to the Ordinance of the Minister of Health of 6 November, 2013, regarding guaranteed 
services in the field of dental treatment (Journal of Laws, item 1462)
Art. 31 c
117
Adaptation visit for children under the age of 4, as part of the benefits included in Annex 3 to the 
Regulation of the Minister of Health of 6 November, 2013 on guaranteed benefits in the field of dental 
treatment (Journal of Laws, item 1462)
Art. 31 c
142 Combined therapy of mechanical clearing of intracerebral arteries with the administration of a fibrinolytic medicine in the acute phase of ischemic stroke Art. 31 c
149 Analgesic treatment of drug-resistant bone metastases using non-invasive thermoablation with a focused ultrasound beam under magnetic resonance control. At. 31 c
160 Prophylactic dental care for children aged 3 Art. 31 c
168 Planning works on the verification of lists of guaranteed benefits included in the regulations of the Minister of Health Art. 31 n (5)
212 Bioresorbable technology in percutaneous coronary intervention Art. 31 n (5)
213 X-ray diagnostics for 5 intraoral images Art. 31 c
214 Prophylactic protection of fissures with other materials Art. 31 c
215 Endodontic treatment of a tooth with unformed root Art. 31 c
216 Dental examination and check-up following tooth injury Art. 31 c
217 Sealants in primary teeth Art. 31 c
218 Prophylactic protection of fissures with dental sealants for second permanent molar teeth Art. 31 c
219 X-ray diagnostics – pantomography image with description Art. 31 c
2014
30 Diagnosis of patients with syncope using an implantable arrhythmia recorder Art. 31 n (5)
185 Based on available HTA reports, indicating recommendations or experiences of international expert circles, qualification criteria (or relative and absolute contraindications) for cataract surgery Art. 31 n (5)
236 Raising the age limit of children covered by the guaranteed benefit, titled ‘prophylactic protection of fissures with dental sealants – for each tooth’ to the age of 8 Art. 31 f
2013
47 Surgical treatment of colon cancer using a robotic system Art. 31 c
48 Surgical treatment of prostate cancer using a robotic system Art. 31 c
49 Surgical treatment of endometrial cancer using a robotic system Art. 31 c
56 Mechanical cardiac support with implantable pumps of the latest generation identified by highly specialized procedures: 13.1 to 13.5 for highly specialized benefits Art. 31 c
209 Assessment of hyperbaric oxygen therapy in monoplace chambers and preparation of a summary report in the subject area Art. 31 n (5)
217
Dental materials used to provide services for the beneficiaries, contained in Annex 12 to the Regulation 
of the Minister of Health of 30 August 2009 on guaranteed benefits in the field of dental treatment 
(Journal of Laws of 2009, No. 140, item 1144 as amended) and the related financial consequences
Art. 31 n (5)
2012
10 Selective Internal Radiation Therapy (SIRT) using Y-90 microspheres (SIR-Spheres) Art. 31 n (5)
15 Hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) Art. 31 n (5)
16 Sanatorium / Spa treatment for adults Art. 31 e
17 Spa rehabilitation for adults in a sanatorium Art. 31 e
32 Hemodiafiltration  (HDF) Art. 31 c
33 Percutaneous renal denervation (PRD) in the treatment of resistant hypertension Art. 31 c
38 Rehabilitation of a patient following a stroke, with upper limb spasticity, treated with topical adminis-tration of botulinum toxin, which will be carried out under the conditions specified in the order Art. 31 c
94 Treatment of acute or chronic graft-versus host disease [GvHD] resistant to corticosteroids, using extracorporeal photopheresis [ECP] Art. 31 c
95 Hybrid cardiac rehabilitation Art. 31 c
99
Change in financing both lungs transplantation in adults and children with cystic fibrosis – option 3.3 
as a variant, highly specialized benefit No. 3 ‘lung transplantation’, financed from the state budget at 
the disposal of the minister competent for health
Art. 31 n (5)
Zeszyty Naukowe Ochrony Zdrowia194
the assessment of non-drug technologies
MZ order 
number in 
a given year
The scope of the MZ order
Legal basis – Act on 
healthcare services 
financed from public 
funds [6]
100
Separating new variants:
1) lung transplantation in patients with primary pulmonary hypertension – 3.4;
2) transplantation of both lungs in patients with primary pulmonary hypertension – 3.5;
– as variants of 3.4 and 3.5, highly specialized benefit No. 3 ‘lung transplantation’, financed from the 
state budget at the disposal of the minister competent for health
Art. 31 n (5)
101 Qualifying as a guaranteed benefit a highly specialized benefit; mechanical cardiac support with the latest generation of implantable pumps, identified using highly specialized procedures: 13.1 to 13. 5 Art. 31 n (5)
119 Transcatheter non-operational mitral valve repair (MitraClip) in high-risk patients,implemented in the scope of highly specialized benefits Art. 31 c
Nevertheless, the abovementioned methods have their 
limitations and should be reserved for unique situations 
where a traditional randomized clinical trial cannot be 
performed. In this situation, the inference regarding clini-
cal effectiveness can be based on reports of lower reliabi-
lity, also observational studies. All the same, randomized 
clinical trials remain the preferred standard for assessing 
the effectiveness of prophylaxis or therapy using medical 
devices [11].
The Medical Technology Assessment Guidelines, is-
sued by AOTMiT in the year 2016, apply only to drug 
technologies [12]. However, there are no Polish guideli-
nes for non-drug technology assessment that would con-
tain detailed rules defining the method and scope of this 
assessment.
It seems that also in Polish conditions it would be 
useful to develop transparent and reliable principles 
used in the assessment of medical devices, including the 
methods of health technology assessment. Guidelines for 
the assessment of medical devices corresponding to those 
developed for drug technologies would allow to determi-
ne the optimal standard of data needed to demonstrate the 
effectiveness, safety and cost-effectiveness of medical 
devices, and explain how deviations from these standards 
affect the assessment of specific products. 
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